Given the fact that most endo doctors are reluctant to prescribe Afrezza yet due to poor FDA label, a slow launch may be a wise strategy for Mannkind. Since Mannkind will share the marketing expense, a heavy spending of AD now may not be effective in driving up scripts but would cause Mannkind a lot of expense on its income statement. A slow launch will minimize Mannkind's expense, while allow patient sponsered trial of Afrezza with the single goal to achieve best A1C number. Now there are 2000 patients trying out Afrezza, and they are going to report back their results to their endo over the next three months. If majority of them can achieve significant A1C reduction, it will certainly change endo's mind about Afrezza. A DTC ad campaign by then will be much more effective. So the next three months will be interesting time.
INO needs to secure the funding before starting VGX-3100 P3.
my guess is Mr. Haakan exercised his stock option and sold a small portion to pay tax. When a person exercise stock option and plan to hold it for long-term capital gain, he still need to pay some tax due to AMT on the differenc between exercise price and market price.
Most medical providers won't eagerly prescribe afrezza initially because FDA label indicates Afrezza is only non-inferior compared to injected insulin. However, once the A1C data comes in from early afrezza users (3 months after starting afrezza), most medical providers will get shocked by how well afrezza can lower A1C. By then, they will change their tune and start introducing afrezza to their patients. So Q2 will be interesting to watch as new A1C data start to coming back to doctors.
The initial goal of 24 to 48 hours window was just too ambitious. That's the problem with skipping Phase 1 trial.
ATHX should start with focusing on treatment within 24 hours, and plan extended treatment window trial after drug is approved.
This is truly great news. One thing concerned me in the past is future dilution of CSLN shares. The revenue stream will provide some relief.
If prescriptions is 3-month supply, then the refill number will closely follow the script number 3 months ago.
The pattern is very similar to ACAD P3 result time. ACAD stock price ran up from $1.5 to $2.8, Then drifted lower to around $2.4 before the anouncement. The only thing worried me a little is the last two days volume. It's a little bit too high. It could be either (1) result leaked out, or (2) people still remember UC trial failure and decide to sell stocks before announcement.
with each early adopting doctor getting more comfortable to prescribe Afrezza, and more doctors starting to prescribing Afrezza, I think it's not hard to double NRX from last week. shoot for 450 NRX.
2U seems useful as correction dose for some patients. It's definitely a good suggestion. When people can do more correction without worrying about hypo, they will get better results.
not necessary. Volume is needed during breaking out session. Now athx is already on clear uptrend.
Great article. The convenience and fast act of Afrezza makes it possible to do finer control of glucose level.
While Intel definitely wants to buy NVDA, NVDA doesn't need Intel any more, as Jen-sen said NVDA is now a software company.